CTOs on the Move


 
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.imv-inc.com
  • 130 Eileen Stubbs Ave
    Dartmouth, NS CAN B3B 2C4
  • Phone: 902.492.1819

Executives

Name Title Contact Details

Funding

IMV raised $29.5M on 03/11/2019
IMV raised $25.1M on 05/18/2020

Similar Companies

Juneau Biosciences

Juneau Biosciences is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syngenta Biotechnology Inc

Syngenta Biotechnology Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vericel

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.

Arisaph Pharmaceuticals

Arisaph Pharmaceuticals is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ocera Therapeutics

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.